Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Journal of Medicinal Chemistry|January 20, 2017
Identification of the First Selective Activin Receptor-Like Kinase 1 Inhibitor, a Reversible Version of L-783277Hanna Cho, Sandip Sengupta, Sean S H Jeon, et al.
European Journal of Medicinal Chemistry|August 22, 2018
Design, synthesis and biological evaluation of novel thiazolidinedione derivatives as irreversible allosteric IKK-β modulatorsAhmed Elkamhawy, Nam Youn Kim, Ahmed H E Hassan, et al.
Bioorganic & Medicinal Chemistry Letters|August 1, 2008
Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinaseWooyoung Hur, Anastasia Velentza, Sungjoon Kim, et al.
ACS Chemical Biology|April 19, 2013
Discovery of a selective irreversible BMX inhibitor for prostate cancerFeiyang Liu, Xin Zhang, Ellen Weisberg, et al.
Bioorganic & Medicinal Chemistry|March 9, 2024
Discovery of N-benzylbenzamide-based allosteric inhibitors of Aurora kinase AHyomin Lee, Euijung Kim, Narae Hwang, et al.
European Journal of Medicinal Chemistry|June 20, 2017
Structure-activity relationship investigation for benzonaphthyridinone derivatives as novel potent Bruton's tyrosine kinase (BTK) irreversible inhibitorsBeilei Wang, Yuanxin Deng, Yongfei Chen, et al.
The Journal of Biological Chemistry|January 7, 2012
Kinome-wide selectivity profiling of ATP-competitive mammalian target of rapamycin (mTOR) inhibitors and characterization of their binding kineticsQingsong Liu, Sivapriya Kirubakaran, Wooyoung Hur, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 29, 2014
Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitorsLi Tan, Jun Wang, Junko Tanizaki, et al.
Cancer Research|February 26, 2013
Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATRQingsong Liu, Chunxiao Xu, Sivapriya Kirubakaran, et al.
Science (New York, N.Y.)|November 15, 2014
Patient-derived models of acquired resistance can identify effective drug combinations for cancerAdam S Crystal, Alice T Shaw, Lecia V Sequist, et al.
Pageof 5